Adore: Integrating Oncology and Neuroscience Research.
Adore is an initiative of Amsterdam UMC, Cancer Center Amsterdam, Alzheimercenter Amsterdam, MS Center Amsterdam, and Amsterdam Neuroscience. The Amsterdam UMC/VU campus comprises over 2000 oncology and neurology researchers, making it the largest onco-neuro campus worldwide. By integrating expertise in neurology and oncology, Adore fosters interdisciplinary collaboration and facilitates the exchange of knowledge between these fields. Our mission is to tackle critical healthcare challenges related to cancer and neurodegenerative diseases and accelerate affordable healthcare solutions for all. We believe that disruptive thinking outside the established disease siloes, facilitating a comprehensive ecosystem and inhouse development throughout the entire translational pipeline will accelerate impact. Through this approach, Adore strives to enhance diagnostic accuracy, develop more effective and personalized therapies, and ultimately improve treatment outcomes for these complex conditions.
Pillar of the Adore ecosystem: infrastructure
In October 2024, Adore inaugurated its Research & Diagnostics Center, a cutting-edge facility designed to accelerate breakthroughs at the intersection of oncology and neurodegeneration. By bringing together experts from both fields, the center fosters interdisciplinary collaboration, enabling researchers to uncover shared disease mechanisms and develop innovative diagnostic and therapeutic strategies. Equipped with state-of-the-art laboratories and advanced technologies, the center provides an optimal environment for high-impact research. Key facilities include:
Whole-Body PET Scanner
Enabling high-resolution molecular imaging for precise disease detection, progression tracking, and therapy monitoring.
Advanced Therapy Medicinal Products (ATMP) Labs
Supporting the development and manufacturing of gene and cell-based therapies.
CRISPR Platform
Facilitating genome editing research to explore disease mechanisms and develop targeted interventions.
CANDIDATE Center
A central unit for target- and drug discovery to identify novel treatments for CNS disorders.
Genomics Core Facility
Providing next-generation sequencing (NGS) and other genomic technologies to drive precision medicine and rare mutation identification.
Proteomics Core Resource
Providing next generation mass spectrometry for high-throughput clinical proteomics, development of innovative biomarker applications and personalized medicine.
Cyclotron
Produces radiopharmaceuticals for advanced diagnostics and targeted treatments.
The Research & Diagnostics Center serves as a collaborative hub where among others molecular biologists, clinicians, imaging scientists, biocomputation and AI specialists, neuroscientists, pharmacologists, and immunologists work together to bridge the gap between fundamental research, diagnostics, and therapy development. By integrating expertise across these fields, Adore fosters a dynamic research environment that connects laboratory discoveries to clinical applications, ensuring that advancements in precision diagnostics, biomarker-driven treatments, and next-generation therapies translate into real-world patient benefits.
Researchers from all disciplines are encouraged to engage with the center, leverage its cutting-edge facilities, and collaborate on the next generation of transformative discoveries.